| Title: | Multiparameter prediction of myeloid neoplasia risk |
| Journal: | Nature Genetics |
| Published: | 24 Aug 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37620601/ |
| DOI: | https://doi.org/10.1038/s41588-023-01472-1 |
| URL: | https://www.nature.com/articles/s41588-023-01472-1.pdf |
| Citations: | 25 (25 in last 2 years) as of 8 Aug 2024 |
Publication 9713
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls, finding that disease-specific changes are detectable years before diagnosis. By analyzing differences between 'pre-MN' and controls, we develop and validate Cox regression models quantifying the risk of progression to each myeloid neoplasm subtype. We construct 'MN-predict', a web application that generates time-dependent predictions with the input of basic blood tests and genetic data. Our study demonstrates that many individuals that develop myeloid neoplasms can be identified years in advance and provides a framework for disease-specific prognostication that will be of substantial use to researchers and physicians.</p>
14 Authors
- Muxin Gu
- Sruthi Cheloor Kovilakam
- William G. Dunn
- Ludovica Marando
- Clea Barcena
- Irina Mohorianu
- Alexandra Smith
- Siddhartha P. Kar
- Margarete A. Fabre
- Moritz Gerstung
- Catherine A. Cargo
- Luca Malcovati
- Pedro M. Quiros
- George S. Vassiliou
1 Application
| Application ID | Title |
|---|---|
| 56844 | Understanding clonal haematopoiesis and the preclinical evolution of haematological cancers |
Enabling scientific discoveries that improve human health